Advances in the use of exosomes for the treatment of ALI/ARDS

Liu, Chang; Xiao, Kun; Xie, Lixin

doi:10.3389/fimmu.2022.971189

Cited by 31 publications

(38 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the context of ALI, exosomes have been a subject of significant research interest due to their potential impact on the pathogenesis and resolution of the condition 26 . Several preclinical studies in animal models of ALI have demonstrated the therapeutic potential of exosomes in mitigating lung injury and promoting recovery, suggesting that exosomes could be used as a novel approach for the treatment of ALI in the future 27,28 . Overall, the potential impact of exosomes on ALI reflects their role as key mediators of intercellular communication and their therapeutic potential in modulating inflammatory responses and promoting tissue repair.…”

Section: Introductionmentioning

confidence: 99%

Umbilical cord MSC‐derived exosomes improve alveolar macrophage function and reduce LPS‐induced acute lung injury

Cui,

Lv,

Wang

et al. 2024

J of Cellular Biochemistry

View full text Add to dashboard Cite

Acute lung injury (ALI) is a severe condition that can progress to acute respiratory distress syndrome (ARDS), with a high mortality rate. Currently, no specific and compelling drug treatment plan exists. Mesenchymal stem cells (MSCs) have shown promising results in preclinical and clinical studies as a potential treatment for ALI and other lung‐related conditions due to their immunomodulatory properties and ability to regenerate various cell types. The present study focuses on analyzing the role of umbilical cord MSC (UC‐MSC))‐derived exosomes in reducing lipopolysaccharide‐induced ALI and investigating the mechanism involved. The study demonstrates that UC‐MSC‐derived exosomes effectively improved the metabolic function of alveolar macrophages and promoted their shift to an anti‐inflammatory phenotype, leading to a reduction in ALI. The findings also suggest that creating three‐dimensional microspheres from the MSCs first can enhance the effectiveness of the exosomes. Further research is needed to fully understand the mechanism of action and optimize the therapeutic potential of MSCs and their secretome in ALI and other lung‐related conditions.

show abstract

Section: Introductionmentioning

confidence: 99%

Umbilical cord MSC‐derived exosomes improve alveolar macrophage function and reduce LPS‐induced acute lung injury

Cui,

Lv,

Wang

et al. 2024

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…In clinics, the primary treatment for ALI/ARDS mainly focuses on symptomatic therapy including mechanical ventilation and fluid management. However, due to the lack of effective therapeutic strategies, the prognosis for most ALI/ARDS patients is despondent (Liu et al 2022b ). The pathogenesis of ALI/ARDS has revealed inflammation plays a pivotal role (Mokrá 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Safflor Yellow A Protects Beas-2B Cells Against LPS-Induced Injury via Activating Nrf2

Chen

Zheng

2023

Rev. Bras. Farmacogn.

View full text Add to dashboard Cite

Acute lung injury and its severe form acute respiratory distress syndrome are lethal lung diseases. So far, effective therapy for the diseases is deficient and the prognosis is poor. Recently, it was found activating nuclear factor erythroid 2-related factor 2 could attenuate the injury including inflammation, oxidative stress, and apoptosis in those diseases. To discover novel therapy, we have evaluated safflor yellow A and explored the underlying mechanisms using Beas-2B cells injured by lipopolysaccharide. As a result, safflor yellow A could improve the viability of Beas-2B cells treated with lipopolysaccharide. Further investigations have revealed safflor yellow A suppressed oxidative stress induced by lipopolysaccharide via reducing reactive oxygen species and malondialdehyde, and elevating superoxide dismutase, catalase, and glutathione peroxidase. Meanwhile, the inflammation resulting from lipopolysaccharide was ameliorated through decreasing the pro-inflammatory cytokines including tumor necrosis factor-α, interleukin-1β, and interleukin-6. It was also found nuclear factor κB was inactivated by safflor yellow A. In addition, safflor yellow A downregulated cysteinyl aspartate specific proteinase-3 and Bcl-2-associated X protein and upregulated B-cell lymphoma-2 to inhibited apoptosis of Beas-2B cells induced by lipopolysaccharide. The activation of nuclear factor erythroid 2-related factor 2 was observed in Beas-2B cells, which was associated with the protective effects of safflor yellow A. And molecular docking elucidated safflor yellow A interacted with Kelch-like ECH-associated protein 1 to activate nuclear factor erythroid 2-related factor 2. These results can provide evidences for the discovery of novel therapy for further evaluation of safflor yellow A in the treatment of acute lung injury and acute respiratory distress syndrome. Graphical Abstract

show abstract

“…[ 2 ] Currently, there have no specific therapies for ALI/ARSD. [ 3 ] The progression of ALI is a series of biological cascade reactions characterized by processes such as alveolar epithelial cells injury, neutrophils infiltration, hyaline membranes formation, alveolar edema, inflammation, and eventually fibrosis. [ 4 ] During the progression of ALI, reactive oxygen species (ROS) generated by the lung itinerant and resident leukocytes, lung parenchymal cells, circulating oxidant‐generating enzymes, and inhaled oxygen are overproduced.…”

Section: Introductionmentioning

confidence: 99%

“…[2] Currently, there have no specific therapies for ALI/ARSD. [3] The progression of ALI is a series of biological cascade reactions characterized by processes such as alveolar epithelial cells injury, neutrophils infiltration, hyaline membranes formation, the lung targeted accumulation. Nevertheless, the construction of ceria nanowires that are suitable for in vivo application has not yet been achieved because the previously synthesized ceria nanowires were too big in both diameter and length, [18] which could not be well stabilized in water or physiological solution.…”

Section: Introductionmentioning

confidence: 99%

Length‐Controlled Construction of Ceria Nanowires with Ultrafine Diameter and Stable Morphology for Targeted Acute Lung Injury Therapy

Liu

Shi

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

The overproduction of reactive oxygen species (ROS) is one of the major reasons for the aggravation of acute lung injury (ALI). Smaller‐sized ceria nanoparticles featured with higher ROS scavenging capability than their bigger‐sized counterparts are potential candidates for ALI therapy. However, smaller‐sized ceria nanoparticles are more easily accumulated in spleen and liver rather than lung. Herein, it is reported that this obstacle can be addressed by constructing ceria into ultrafine nanowires, through which the ultrafine diameter ensures the high ROS scavenging activity and the high aspect ratio promotes the lung targeted accumulation. To demonstrate the feasibility of this conception, a platform is developed to realize length‐controlled ceria nanowires (diameter of ≈1.5 nm) synthesis. These nanowires are PEGylated using a carefully optimized procedure that can preserve their fragile crystal structures. The PEGylated nanowires exhibit higher ROS scavenging capabilities than the ≈3.9 nm sized nanoparticles. Most importantly, lung targeted accumulation can be realized through modulating the length of the nanowires, where the longer nanowires (>100 nm) show much higher lung accumulation. Due to these properties, the longer ceria nanowires can effectively scavenge the overproduced ROS during the progression of ALI, and thereby inhibit the edema and inflammation in the lung tissue.

show abstract

Advances in the use of exosomes for the treatment of ALI/ARDS

Cited by 31 publications

References 150 publications

Umbilical cord MSC‐derived exosomes improve alveolar macrophage function and reduce LPS‐induced acute lung injury

Umbilical cord MSC‐derived exosomes improve alveolar macrophage function and reduce LPS‐induced acute lung injury

Safflor Yellow A Protects Beas-2B Cells Against LPS-Induced Injury via Activating Nrf2

Length‐Controlled Construction of Ceria Nanowires with Ultrafine Diameter and Stable Morphology for Targeted Acute Lung Injury Therapy

Contact Info

Product

Resources

About